Using A3AR agonists to reduce brain damage from chemotherapy
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity
This study is looking at how a special type of medication might help improve thinking and memory problems, often called 'chemobrain,' that many people experience during chemotherapy for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10460227 on NIH RePORTER |
What this research studies
This research investigates how A3 adenosine receptor agonists can help mitigate cognitive impairment, often referred to as 'chemobrain', which affects over half of chemotherapy patients. The study aims to understand the mechanisms behind this neurotoxicity and explore new therapeutic options that could be quickly implemented in clinical settings. By examining changes in brain function and structure caused by chemotherapy, the research seeks to identify potential interventions that could protect cognitive health during cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are undergoing chemotherapy and experiencing cognitive difficulties.
Not a fit: Patients who are not undergoing chemotherapy or those with pre-existing cognitive impairments unrelated to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reduce cognitive impairment in cancer patients undergoing chemotherapy.
How similar studies have performed: While the approach of targeting A3 adenosine receptors is novel, preliminary data suggest that similar mechanisms have shown promise in other studies related to neurotoxicity.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Salvemini, Daniela — Saint Louis University
- Study coordinator: Salvemini, Daniela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.